Fig. 6
From: Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation
DOACs versus warfarin in AF patients with different HbA1c categories. Overall, DOACs were associated with a lower risk of IS/SE (adjusted HR 0.61, 95% CI 0.49–0.75, P < 0.0001) and major bleeding (adjusted HR 0.30, 95% CI 0.21–0.42, P < 0.0001) without interactions across different HbA1c categories (P interaction > 0.05 for both endpoints). *Risk of IS/SE was adjusted for CHA2DS2-VASc score, use of insulin or OHAs, and eGFR. †Risk of major bleeding was adjusted for HAS-BLED score, use of insulin or OHAs, and eGFR. AF atrial fibrillation, aHR adjusted hazard ratio, CI confidence interval, DOAC direct oral anticoagulant, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin A1c, IS/SE ischemic stroke/systemic embolism